British Peripheral Nerve Society

This meeting is open to BPNS members and other professionals working in relevant areas, but not to patients or members of the general public without advance permission.
This event is fully booked.

Meal after Hammersmith Meeting - Non-Vegetarian option

Start Date

End Date

Friday 17 Oct 2025 17:45 PM

Friday 17 Oct 2025 19:45 PM

Location

Imm Thai Cafe, 308 Latimer Rd, London W10 6QW

Details

NON-Vegetarian option for meal after Hammersmith meeting

Please register early as spaces will be limited

https://immthaicafe.co.uk/

Please pay by bank transfer to BPNS when you register for this meal - drinks NOT included

(£35 to account number 30216135; sort code 20 17 35) Reference SURNAME THAI

We’ve booked this tiny but excellent family run Thai place 10 mins walk from the Hammersmith for a post-meeting early meal. Maximum 24 people – which will fill it, so book early.

4.8 on Tripadvisor. “Amazing restaurant. Amazing food. Amazing staff – highly recommend.” “A hidden gem.” “As good as you would get in Thailand.”

Lost driving licence

Jiten Mistry misplaced his driving licence at the Belfast meeting. If anyone picked it up, please could they contact him at jitenmistry@nhs.net.

Queen Square Annual Update in Neuromuscular Disorders

This course will be held from Wednesday 13th May to Friday 15th May in the Clinical Neuroscience Lecture Theatre, Lower ground, 33 Queen Square, London WC1N 3BG

DETAILS/REGISTRATION

Brain Fellowships

Applications are invited for 1 year fellowships funded by the Guarantors of Brain. These fellowships provide bridging salary support to early career clinicians based in the UK prior to obtaining a research fellowship. Further details can be found HERE

New NHSE commissioning policies for rituximab and IVIg

We are pleased to announce that, largely due to the efforts of our president Prof Lunn, rituximab is now approved for treatment of IgM paraproteinaemic demyelinating peripheral neuropathy (anti-MAG phenotype, with or without anti-MAG antibodies): 1910-rituximab-for-treatment-of-PDPN-policy-v2.pdf (england.nhs.uk). Whilst we have hitherto been able to treat some patients with rituximab by sending them to a haematologist, this was not possible if the bone marrow showed insufficient evidence of underlying lymphoplasmacytic lymphoma. These patients can now be treated, regardless of bone marrow result, either by you or by your friendly haematologist, under the new commissioning guidance.
Also thanks to Prof Lunn (alongside non-neurology colleagues), the updated IVIg commissioning policy is now available: Commissioning-Criteria-Policy-for-the-use-of-Ig-Version-Finala.pdf (mdsas.com). Newly commissioned diagnoses of relevance to peripheral nerve now include acute autoimmune autonomic ganglionopathy, and neuromyotonia.
Finally, with thanks largely to the efforts of Dr Rinaldi in Oxford, rituximab can now be used for the treatment of autoimmune nodopathies (with nodal/paranodal antibodies): NHS England » Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children.

More news »

Meetings

Lost driving licence

Queen Square Annual Update in Neuromuscular Disorders

Brain Fellowships

New NHSE commissioning policies for rituximab and IVIg